Event Details
January 01, 2018
Description
Changes in Swiss law regarding pharmaceutical grade pure CBD following US FDA approval of Epidiolex.
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
| Swiss Government | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024898.jpg
This document is page 82 of a Cowen Collaborative Insights report dated February 25, 2019, analyzing the cannabis and hemp markets in Italy and Switzerland. It details regulatory environments, specifically the 'cannabis light' market in Italy and medical/tobacco substitute regulations in Switzerland, while listing various corporate investments and acquisitions (Wayland, Canopy, CROP). The document bears a 'HOUSE_OVERSIGHT_024898' Bates stamp, indicating it was part of a document production to the House Oversight Committee, likely included in a larger batch of financial records.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA gave green light for Geron clinical trial.
2009-01-01 • US
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
Previous FDA guidance on botanical drugs issued.
2004-06-01 • USA
FDA convened meeting to analyze drug data.
Date unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event